Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:AVDLNASDAQ:RNANASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$63.82+1.5%$62.39$47.86▼$107.37$3.47B0.28605,558 shs409,507 shsAVDLAvadel Pharmaceuticals$9.32-0.5%$8.94$6.38▼$17.30$906.44M1.451.27 million shs1.27 million shsRNAAvidity Biosciences$29.32-0.1%$30.28$21.51▼$56.00$3.54B0.951.41 million shs990,714 shsSWTXSpringWorks Therapeutics$46.78-0.2%$44.67$28.21▼$62.00$3.53B0.72.44 million shs8.07 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+1.49%-3.55%+9.08%-10.60%+18.60%AVDLAvadel Pharmaceuticals-0.53%-5.76%-0.32%+7.50%-40.26%RNAAvidity Biosciences-0.14%-8.40%-2.98%-4.90%-23.51%SWTXSpringWorks Therapeutics-0.17%+0.06%+1.10%-8.42%+29.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.511 of 5 stars3.53.00.00.02.02.50.0AVDLAvadel Pharmaceuticals2.2191 of 5 stars3.51.00.00.02.61.70.6RNAAvidity Biosciences1.9987 of 5 stars4.50.00.00.02.00.80.0SWTXSpringWorks Therapeutics1.5904 of 5 stars3.12.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.2374.29% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.1794.92% UpsideRNAAvidity Biosciences 3.06Buy$66.56127.02% UpsideSWTXSpringWorks Therapeutics 2.13Hold$52.5712.38% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, RNA, ACLX, and SWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/17/2025RNAAvidity BiosciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/11/2025RNAAvidity BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$65.006/10/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $75.006/10/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/10/2025RNAAvidity BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/9/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.006/9/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $75.005/12/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $68.005/12/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M32.58N/AN/A$8.41 per share7.59AVDLAvadel Pharmaceuticals$169.12M5.33N/AN/A$0.77 per share12.10RNAAvidity Biosciences$10.90M324.19N/AN/A$11.94 per share2.46SWTXSpringWorks Therapeutics$191.59M18.40N/AN/A$6.47 per share7.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A155.33N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)SWTXSpringWorks Therapeutics-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)Latest AVDL, RNA, ACLX, and SWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SWTXSpringWorks Therapeutics-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.934.93AVDLAvadel PharmaceuticalsN/A2.732.33RNAAvidity BiosciencesN/A16.9116.91SWTXSpringWorks TherapeuticsN/A4.334.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AVDLAvadel Pharmaceuticals69.19%RNAAvidity BiosciencesN/ASWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AVDLAvadel Pharmaceuticals4.80%RNAAvidity Biosciences3.83%SWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.51 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million92.10 millionOptionableRNAAvidity Biosciences190120.52 million115.90 millionOptionableSWTXSpringWorks Therapeutics23075.35 million69.45 millionOptionableAVDL, RNA, ACLX, and SWTX HeadlinesRecent News About These CompaniesGAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)June 19 at 3:03 AM | marketbeat.comComparing SpringWorks Therapeutics (NASDAQ:SWTX) & Genenta Science (NASDAQ:GNTA)June 18 at 2:54 AM | americanbankingnews.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by AnalystsJune 17 at 3:14 AM | marketbeat.comBiotech Stocks To Consider - June 16thJune 16 at 2:11 PM | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - Here's WhyJune 16 at 1:21 PM | marketbeat.comFNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 16 at 7:44 AM | marketbeat.comAssenagon Asset Management S.A. Takes $3.52 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 16 at 3:56 AM | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?June 9, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLCJune 5, 2025 | marketbeat.comRFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 4, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 4, 2025 | marketbeat.comSPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTXJune 3, 2025 | businesswire.comNuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 31, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 28, 2025 | marketbeat.comSpringWorks Therapeutics (SWTX) Surged on Acquisition NewsMay 27, 2025 | msn.comSpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challengesMay 27, 2025 | investing.comSpringWorks Gets CHMP Nod for Mirdametinib in Rare DiseaseMay 26, 2025 | zacks.comProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 26, 2025 | marketbeat.comDeutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 25, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from AnalystsMay 25, 2025 | marketbeat.comPalisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsAVDL, RNA, ACLX, and SWTX Company DescriptionsArcellx NASDAQ:ACLX$63.82 +0.94 (+1.49%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$63.80 -0.02 (-0.03%) As of 06/18/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Avadel Pharmaceuticals NASDAQ:AVDL$9.32 -0.05 (-0.53%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.32 0.00 (0.00%) As of 06/18/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Avidity Biosciences NASDAQ:RNA$29.32 -0.04 (-0.14%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$29.06 -0.27 (-0.90%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.SpringWorks Therapeutics NASDAQ:SWTX$46.78 -0.08 (-0.17%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$46.79 +0.01 (+0.02%) As of 06/18/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
